Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Otofarma SpAMIL:OTO -1.50%16 Debt-to-Equity is 0.57 as of Dec. 2024, which is 5% below its 10-year median of 0.60. GuruFocus rates MIL:OTO with a GF Score™ of 16/100. The stock has 1 warning sign investors should review. Among 705 Medical Devices & Instruments companies, Otofarma SpA ranks worse than 72.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Otofarma SpA's Debt-to-Equity or its related term are showing as below:
MIL:OTO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.57 Med: 0.6 Max: 0.63
Current: 0.57
During the past 2 years, the highest Debt-to-Equity Ratio of Otofarma SpA was 0.63. The lowest was 0.57. And the median was 0.60.
MIL:OTO's Debt-to-Equity is ranked worse than 72.2% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs MIL:OTO: 0.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Otofarma SpA Debt-to-Equity Related Terms
Otofarma SpA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Otofarma SpA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otofarma SpA Debt-to-Equity Chart
Otofarma SpA Annual Data
Trend
Dec23
Dec24
Debt-to-Equity
0.63
0.57
Otofarma SpA Semi-Annual Data
Dec23
Dec24
Debt-to-Equity
0.63
0.57
MIL:OTO vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Otofarma SpA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otofarma SpA Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Otofarma SpA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Otofarma SpA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otofarma SpA (MIL:OTO) has a Debt-to-Equity of 0.57 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Otofarma SpA and its competitors. This is near median its historical median of 0.60. Over the past decade, Otofarma SpA's Debt-to-Equity has ranged from 0.57 to 0.63. According to the industry distribution chart, Otofarma SpA ranks #509 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 72.2%.
Is Otofarma SpA's Debt-to-Equity too high?
Otofarma SpA's current Debt-to-Equity of 0.57 is near median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 0.63. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Otofarma SpA's value of 0.57 is 147.8% above this industry median. Based on the distribution chart, Otofarma SpA ranks #509 out of 705 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Otofarma SpA has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Otofarma SpA's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Otofarma SpA ranks #509 out of 705 companies for Debt-to-Equity. This places Otofarma SpA in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Otofarma SpA's value of 0.57 is 147.8% above this benchmark. Historically, Otofarma SpA's own Debt-to-Equity has ranged from 0.57 to 0.63 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 0.23, Otofarma SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Otofarma SpA's current Debt-to-Equity of 0.57 is 147.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Otofarma SpA and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Otofarma SpA's current Debt-to-Equity is 0.57, which is near median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otofarma SpA stock overvalued right now?
Otofarma SpA (MIL:OTO) has a current Debt-to-Equity of 0.57. The current Debt-to-Equity is 0.57, which is near median its 10-year median of 0.60 and 147.8% above the Medical Devices & Instruments industry median of 0.23. Otofarma SpA's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Otofarma SpA (MIL:OTO), the current Debt-to-Equity is 0.57 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Otofarma SpA is engaged in the construction and production of hearing aids, is constantly growing in the audiological field to provide adequate responses to every type of hearing aid need to its customers who require the possible personalized application of custom-made hearing aids. It provides otoacoustic medical devices and TELEMEDICINE services exclusively in affiliated pharmacies, possessing a portfolio of Instrumental IT patents.
16GF Score
Get the complete analysis for MIL:OTO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:OTO has been successfully added to your 
